GlaxoSmithKline (LON:GSK) received a GBX 1,600 ($22.46) price target from research analysts at UBS in a research report issued on Thursday. The brokerage presently has a “buy” rating on the stock. UBS’s target price would indicate a potential upside of 12.47% from the company’s current price.
A number of other equities research analysts also recently weighed in on the company. Credit Suisse Group raised their target price on GlaxoSmithKline from GBX 1,300 ($18.25) to GBX 1,450 ($20.35) and gave the company a “neutral” rating in a report on Tuesday. Morgan Stanley set a GBX 1,400 ($19.65) price objective on GlaxoSmithKline and gave the company a “neutral” rating in a report on Tuesday. Kepler Capital Markets raised their price objective on GlaxoSmithKline from GBX 1,360 ($19.09) to GBX 1,400 ($19.65) and gave the company a “hold” rating in a report on Wednesday, March 28th. Berenberg Bank raised their price objective on GlaxoSmithKline from GBX 1,705 ($23.93) to GBX 1,780 ($24.99) and gave the company a “buy” rating in a report on Wednesday, March 28th. Finally, HSBC reissued a “buy” rating and set a GBX 2,030 ($28.50) price objective on shares of GlaxoSmithKline in a report on Wednesday, March 28th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and nine have issued a buy rating to the stock. GlaxoSmithKline currently has an average rating of “Hold” and an average target price of GBX 1,548.64 ($21.74).
Shares of GSK stock opened at GBX 1,422.60 ($19.97) on Thursday. GlaxoSmithKline has a fifty-two week low of GBX 1,235.20 ($17.34) and a fifty-two week high of GBX 1,724.50 ($24.21).
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.